← Patent-cliff monitor small molecule IMBRUVICA IBRUTINIB
Loss of exclusivity September 2036 latest FDA-listed patent expiry
Drug detail Brand name IMBRUVICA Active ingredient IBRUTINIB Strength 280MG Dosage form TABLET Route ORAL Modality Small molecule FDA approval February 2018 Marketing status RX
Listed patents Patent Expires Type 9655857*PED September 2036 — 10010507*PED September 2036 — 10213386*PED September 2036 — 10828259*PED September 2036 — 10828259 March 2036 product 12551448 March 2036 product 10010507 March 2036 product 10213386 March 2036 product 9655857 March 2036 product 10463668*PED April 2035 — 9795604*PED April 2035 — 10695350*PED April 2035 — 10695350 October 2034 use U-2846 9795604 October 2034 use U-2970 10463668 October 2034 use U-2654 9296753*PED April 2034 — 10106548*PED December 2033 — 10961251*PED December 2033 — 9725455*PED December 2033 — 10125140*PED December 2033 — 9296753 October 2033 substance 10961251 June 2033 product 10106548 June 2033 substance, product 10125140 June 2033 substance, product 9725455 June 2033 substance 10004746*PED December 2031 — 9125889*PED December 2031 — 9801883*PED December 2031 — 10016435*PED December 2031 — 10478439*PED December 2031 — 8999999*PED December 2031 — 9801881*PED December 2031 — 10751342*PED December 2031 — 11672803 June 2031 use U-2242 9801883 June 2031 use U-2159 9125889 June 2031 use U-1650 8999999 June 2031 use U-1491 9801881 June 2031 use U-2242 10004746 June 2031 use U-2242 10016435 June 2031 use U-1650 10478439 June 2031 use U-3422 10751342 June 2031 use U-1491 8008309*PED May 2028 — 8008309 November 2027 substance, product 8563563*PED October 2027 — 8754091*PED June 2027 — 8952015*PED June 2027 — 7514444*PED June 2027 — 8476284*PED June 2027 — 8957079*PED June 2027 — 8703780*PED June 2027 — 8735403*PED June 2027 — 8497277*PED June 2027 — 9181257*PED June 2027 — 8697711*PED June 2027 — 8563563 April 2027 use U-2241 8703780 December 2026 use U-1491 8697711 December 2026 substance, product 9181257 December 2026 substance 8735403 December 2026 substance, product 7514444 December 2026 substance, product 8957079 December 2026 substance, product 8754091 December 2026 product 8497277 December 2026 use U-3422 8476284 December 2026 use U-1946 8952015 December 2026 use U-1491
Regulatory exclusivity Code Expires PED February 2030 ODE-405 August 2029 PED February 2026 NPP August 2025
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.